115 related articles for article (PubMed ID: 38211842)
1. ALDH1A3 contributes to tumorigenesis in high-grade serous ovarian cancer by epigenetic modification.
Huang J; Tang Y; Li Y; Wei W; Kang F; Tan S; Lin L; Lu X; Wei H; Wang N
Cell Signal; 2024 Apr; 116():111044. PubMed ID: 38211842
[TBL] [Abstract][Full Text] [Related]
2. Differential gene expression identifies a transcriptional regulatory network involving ER-alpha and PITX1 in invasive epithelial ovarian cancer.
Li Y; Jaiswal SK; Kaur R; Alsaadi D; Liang X; Drews F; DeLoia JA; Krivak T; Petrykowska HM; Gotea V; Welch L; Elnitski L
BMC Cancer; 2021 Jul; 21(1):768. PubMed ID: 34215221
[TBL] [Abstract][Full Text] [Related]
3. Integrative analysis reveals early epigenetic alterations in high-grade serous ovarian carcinomas.
Machino H; Dozen A; Konaka M; Komatsu M; Nakamura K; Ikawa N; Shozu K; Asada K; Kaneko S; Yoshida H; Kato T; Nakayama K; Saloura V; Kyo S; Hamamoto R
Exp Mol Med; 2023 Oct; 55(10):2205-2219. PubMed ID: 37779141
[TBL] [Abstract][Full Text] [Related]
4. TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR/autophagy pathway.
Qi G; Ma H; Li Y; Peng J; Chen J; Kong B
Cell Death Dis; 2021 Dec; 12(12):1135. PubMed ID: 34876569
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic Modifier SETD8 as a Therapeutic Target for High-Grade Serous Ovarian Cancer.
Wada M; Kukita A; Sone K; Hamamoto R; Kaneko S; Komatsu M; Takahashi Y; Inoue F; Kojima M; Honjoh H; Taguchi A; Kashiyama T; Miyamoto Y; Tanikawa M; Tsuruga T; Mori-Uchino M; Wada-Hiraike O; Osuga Y; Fujii T
Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33339442
[TBL] [Abstract][Full Text] [Related]
6. HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling.
Khella CA; Franciosa L; Rodirguez-Rodriguez L; Rajkarnikar R; Mythreye K; Gatza ML
Mol Cancer Res; 2023 Oct; 21(10):1037-1049. PubMed ID: 37342066
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-625-3p improved proliferation and involved chemotherapy resistance via targeting PTEN in high grade ovarian serous carcinoma.
Zhong L; Liu X; Wang L; Liu Y; Zhang D; Zhao Y
J Ovarian Res; 2022 Jan; 15(1):7. PubMed ID: 35027053
[TBL] [Abstract][Full Text] [Related]
8. Biological and prognostic value of ETV5 in high-grade serous ovarian cancer.
Zhang L; Fu R; Liu P; Wang L; Liang W; Zou H; Jia W; Tao L
J Ovarian Res; 2021 Nov; 14(1):149. PubMed ID: 34736492
[TBL] [Abstract][Full Text] [Related]
9. PITX1, a specificity determinant in the HIF-1α-mediated transcriptional response to hypoxia.
Mudie S; Bandarra D; Batie M; Biddlestone J; Moniz S; Ortmann B; Shmakova A; Rocha S
Cell Cycle; 2014; 13(24):3878-91. PubMed ID: 25558831
[TBL] [Abstract][Full Text] [Related]
10. CCNG1 (Cyclin G1) regulation by mutant-P53 via induction of Notch3 expression promotes high-grade serous ovarian cancer (HGSOC) tumorigenesis and progression.
Xu Y; Zhang Q; Miao C; Dongol S; Li Y; Jin C; Dong R; Li Y; Yang X; Kong B
Cancer Med; 2019 Jan; 8(1):351-362. PubMed ID: 30565428
[TBL] [Abstract][Full Text] [Related]
11. GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma.
El-Arabey AA; Denizli M; Kanlikilicer P; Bayraktar R; Ivan C; Rashed M; Kabil N; Ozpolat B; Calin GA; Salama SA; Abd-Allah AR; Sood AK; Lopez-Berestein G
Cell Signal; 2020 Apr; 68():109539. PubMed ID: 31935430
[TBL] [Abstract][Full Text] [Related]
12. Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer.
Tomar T; Alkema NG; Schreuder L; Meersma GJ; de Meyer T; van Criekinge W; Klip HG; Fiegl H; van Nieuwenhuysen E; Vergote I; Widschwendter M; Schuuring E; van der Zee AGJ; de Jong S; Wisman GBA
BMC Med; 2017 Jun; 15(1):116. PubMed ID: 28641578
[TBL] [Abstract][Full Text] [Related]
13. Long noncoding RNA NEAT1, regulated by LIN28B, promotes cell proliferation and migration through sponging miR-506 in high-grade serous ovarian cancer.
Yong W; Yu D; Jun Z; Yachen D; Weiwei W; Midie X; Xingzhu J; Xiaohua W
Cell Death Dis; 2018 Aug; 9(9):861. PubMed ID: 30154460
[TBL] [Abstract][Full Text] [Related]
14. MiR-585-3p suppresses tumor proliferation and migration by directly targeting CAPN9 in high grade serous ovarian cancer.
Lu X; Li G; Liu S; Wang H; Chen B
J Ovarian Res; 2021 Jul; 14(1):90. PubMed ID: 34238324
[TBL] [Abstract][Full Text] [Related]
15. ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo.
Li R; Liu T; Shi J; Luan W; Wei X; Yu J; Mao H; Liu P
J Transl Med; 2019 Dec; 17(1):428. PubMed ID: 31878941
[TBL] [Abstract][Full Text] [Related]
16. MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis.
Wang CK; Chen TJ; Tan GYT; Chang FP; Sridharan S; Yu CA; Chang YH; Chen YJ; Cheng LT; Hwang-Verslues WW
Cancer Res; 2023 Jan; 83(2):251-263. PubMed ID: 36354374
[TBL] [Abstract][Full Text] [Related]
17. LGR4 maintains HGSOC cell epithelial phenotype and stem-like traits.
Wang Z; Yin P; Sun Y; Na L; Gao J; Wang W; Zhao C
Gynecol Oncol; 2020 Dec; 159(3):839-849. PubMed ID: 32980127
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological targeting of histone H3K27 acetylation/BRD4-dependent induction of ALDH1A3 for early-phase drug tolerance of gastric cancer.
Lee J; Mashima T; Kawata N; Yamamoto N; Morino S; Inaba S; Nakamura A; Kumagai K; Wakatsuki T; Takeuchi K; Yamaguchi K; Seimiya H
Cancer Res Commun; 2024 Apr; ():. PubMed ID: 38669046
[TBL] [Abstract][Full Text] [Related]
19. Functional analysis of the 1p34.3 risk locus implicates GNL2 in high-grade serous ovarian cancer.
Nakamura K; Reid BM; Chen A; Chen Z; Goode EL; Permuth JB; Teer JK; Tyrer J; Yu X; Kanetsky PA; Pharoah PD; Gayther SA; Sellers TA; Lawrenson K; Karreth FA
Am J Hum Genet; 2022 Jan; 109(1):116-135. PubMed ID: 34965383
[TBL] [Abstract][Full Text] [Related]
20. [Identification of key molecules in miRNA-mRNA regulatory network associated with high-grade serous ovarian cancer recurrence using bioinformatic analysis].
Zhang P; He M; Zeng Y; Cai X
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Jan; 43(1):8-16. PubMed ID: 36856205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]